Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II).


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2022
Historique:
pubmed: 14 12 2021
medline: 28 4 2022
entrez: 13 12 2021
Statut: ppublish

Résumé

Deep brain stimulation of the sub-thalamic nucleus (DBS-STN) reduces symptoms in Parkinson's disease (PD) patients with motor fluctuations. However, some patients may not feel ameliorated afterwards, despite an objective motor improvement. It is thus important to find new predictors of patients' quality of life (QoL) amelioration after DBS-STN. We hypothesized that personality dimensions might affect QoL after DBS-STN. To evaluate associations between personality dimensions and QoL improvement one year after DBS-STN. DBS-STN-PD patients (n = 303) having answered the "Temperament and Character Inventory" (TCI) before surgery and the PDQ-39 before and one year after surgery were included, from the cohort study PREDI-STIM. Linear regression models were used to evaluate associations between TCI dimensions and change in PDQ-39 scores after DBS-STN. Novelty Seeking and Cooperativeness scores before surgery were positively associated with PDQ-39 scores improvement after DBS-STN (FDR-adjusted p < 0.01). Moreover, paradoxically unimproved patients with deterioration of their PDQ-39 scores after DBS-STN despite improvement of their MDS-UPDRS-IV scores had lower Cooperativeness scores, while paradoxically improved patients with amelioration of their PDQ-39 scores despite deterioration of their MDS-UPDRS-IV scores had higher Reward Dependence scores. Some presurgical personality dimensions were significantly associated with QoL amelioration and discrepancy between motor state and QoL changes after DBS-STN in PD. Educational programs before DBS-STN should take in account patient personality dimensions to better deal with their expectations.

Sections du résumé

BACKGROUND
Deep brain stimulation of the sub-thalamic nucleus (DBS-STN) reduces symptoms in Parkinson's disease (PD) patients with motor fluctuations. However, some patients may not feel ameliorated afterwards, despite an objective motor improvement. It is thus important to find new predictors of patients' quality of life (QoL) amelioration after DBS-STN. We hypothesized that personality dimensions might affect QoL after DBS-STN.
OBJECTIVE
To evaluate associations between personality dimensions and QoL improvement one year after DBS-STN.
METHODS
DBS-STN-PD patients (n = 303) having answered the "Temperament and Character Inventory" (TCI) before surgery and the PDQ-39 before and one year after surgery were included, from the cohort study PREDI-STIM. Linear regression models were used to evaluate associations between TCI dimensions and change in PDQ-39 scores after DBS-STN.
RESULTS
Novelty Seeking and Cooperativeness scores before surgery were positively associated with PDQ-39 scores improvement after DBS-STN (FDR-adjusted p < 0.01). Moreover, paradoxically unimproved patients with deterioration of their PDQ-39 scores after DBS-STN despite improvement of their MDS-UPDRS-IV scores had lower Cooperativeness scores, while paradoxically improved patients with amelioration of their PDQ-39 scores despite deterioration of their MDS-UPDRS-IV scores had higher Reward Dependence scores.
CONCLUSION
Some presurgical personality dimensions were significantly associated with QoL amelioration and discrepancy between motor state and QoL changes after DBS-STN in PD. Educational programs before DBS-STN should take in account patient personality dimensions to better deal with their expectations.

Identifiants

pubmed: 34897100
pii: JPD212883
doi: 10.3233/JPD-212883
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

699-711

Auteurs

Mathilde Boussac (M)

Toulouse Neuro Imaging Center, University of Toulouse, Inserm, UPS, France.

Christophe Arbus (C)

Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.

Helene Klinger (H)

Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France.

Alexandre Eusebio (A)

Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.

Elodie Hainque (E)

Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France et Faculté de Médecine de Sorbonne Université, Paris, France.

Jean Christophe Corvol (JC)

Sorbonne Université, Paris Brain Institute -ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, NS-PARK/FCRIN, Department of Neurology, Paris, France.

Olivier Rascol (O)

Toulouse Neuro Imaging Center, University of Toulouse, Inserm, UPS, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.

Vanessa Rousseau (V)

Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.

Estelle Harroch (E)

Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.

Charlotte Scotto d'Apollonia (CS)

Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.

Aurélie Croiset (A)

CERPPS-Study and Research Center in Psychopathology and Health Psychology, University of Toulouse II Jean-Jaurès, Toulouse, France.

Fabienne Ory-Magne (F)

Toulouse Neuro Imaging Center, University of Toulouse, Inserm, UPS, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.

Amaury De Barros (A)

Toulouse Neuro Imaging Center, University of Toulouse, Inserm, UPS, France.
Department of Neurosurgery, Toulouse University Hospital, Toulouse, France.

Margherita Fabbri (M)

Toulouse Neuro Imaging Center, University of Toulouse, Inserm, UPS, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.

Caroline Moreau (C)

Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.

Anne-Sophie Rolland (AS)

Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.

Isabelle Benatru (I)

Neurology Department, University Hospital of Poitiers, Poitiers, France; INSERM, CHU de Poitiers, University of Poitiers, Centre d'Investigation Clinique CIC1402, Poitiers, France.

Mathieu Anheim (M)

Service de Neurologie, Hôpitaux Universitaires de Strasbourg; Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Ana-Raquel Marques (AR)

Université Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand University Hospital, Neurology department, France.

David Maltête (D)

Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France.

Sophie Drapier (S)

CHU Rennes, Service de neurologie, CIC-INSERM 1414, Rennes, France.

Béchir Jarraya (B)

Pôle Neurosciences, Foch Hospital, Suresnes; Université Paris-Saclay, UVSQ, INSERM U992, CEA Paris-Saclay, Neurospin, France.

Cécile Hubsch (C)

Hôpital Fondation A de Rothschild, Service de recherche clinique, Paris, France.

Dominique Guehl (D)

Institut des Maladies Neurodégénératives (IMN, CNRS U5393), Université de Bordeaux, Bordeaux, France.
Service de Neurophysiologie Clinique, Pôle des Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.

Mylène Meyer (M)

Service de neurologie, Hôpital Central, CHRU de Nancy, Nancy Cedex, France.

Tiphaine Rouaud (T)

Clinique Neurologique, Hôpital Guillaume et René Laennec, Boulevard Jacques Monod, Nantes Cedex, France.

Bruno Giordana (B)

CHU Nice, Department of Psychiatry and Psychotherapy, Nice, France.

Mélissa Tir (M)

Department of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens, France.

David Devos (D)

Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.

Christine Brefel-Courbon (C)

Toulouse Neuro Imaging Center, University of Toulouse, Inserm, UPS, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH